Company / Cash & Equivalents
Cooper Companies (The) Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$110.6M
FY2025
5-year range
$95.9M / $138.2M
FY2021-FY2025
Trend
+2.8%
vs FY2024
Sector context
#109 of 152
Health Care
What the data says
At $111M, Cooper Companies (The)'s cash & equivalents ranks #109 of 152 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $111M.
Based on SEC 10-K filings.
$111M in FY2025 with a 5-year CAGR of -0.9%.
Declined from $121M to $111M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -7.2%
- 5-Year CAGR
- -0.9%
- 10-Year CAGR
- -
Sector benchmark
#109 of 152 in Health CareTop 72% of 152This company $110.6M Sector average $1.2B
▼
-90.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 2.8% year-over-year.
- Ranks #109 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $110.6M | +2.8% |
| FY2024 | $107.6M | -10.9% |
| FY2023 | $120.8M | -12.6% |
| FY2022 | $138.2M | +44.1% |
| FY2021 | $95.9M | -17.3% |
| FY2020 | $115.9M | +30.2% |
| FY2019 | $89.0M | +14.5% |
| FY2018 | $77.7M | -12.5% |
| FY2017 | $88.8M | -11.9% |
| FY2016 | $100.8M | +514.6% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026